Dr. Jennifer Weeks, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9040 Fitzsimmons Dr, Joint Base Lewis Mcchord, WA 98431 Phone: 253-986-1330 |
Dr. Karen Bowman, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 690 Barnes Blvd, Joint Base Lewis Mcchord, WA 98438 Phone: 253-982-2222 |
Dr. Keith M Lemmon, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Joint Base Lewis Mcchord, WA 98431 Phone: 253-968-1980 |
Nelson Erik Vick, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9040a Jackson Avenue, Joint Base Lewis Mcchord, WA 98431 Phone: 253-968-3496 |
Ocheze Chikezie-darron, Pediatrics Medicare: Medicare Enrolled Practice Location: Madigan Army Medical Center, Joint Base Lewis Mcchord, WA 98431 Phone: 253-968-2310 |
Dr. Amy Connors, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 690 Barnes Blvd, Mcchord Field, Joint Base Lewis Mcchord, WA 98438 Phone: 253-982-0328 Fax: 253-982-2339 |
Jane Ann Crotteau, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Madigan Army Medical Center 9040a Jackson Ave, Joint Base Lewis Mcchord, WA 98431 Phone: 253-968-1110 |
News Archive
Primary care doctors are reluctant to talk to patients about their drinking habits, for fear of being perceived as judgmental. But a simple, intervention that encourages discussion could resolve this issue, according to a recent study in the Journal of General Internal Medicine.
Zimmer Holdings, Inc. today reported financial results for the quarter ended March 31, 2015. The Company reported first quarter net sales of $1.13 billion, a decrease of 2.3% reported and an increase of 4.5% constant currency compared to the first quarter of 2014.
Scientists have developed a way to see brain cells talk – to actually see neurons communicate in bright, vivid color. The new lab technique is set to provide long-needed answers about the brain and neurological conditions such as Alzheimer's disease, schizophrenia and depression.
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
› Verified 2 days ago